Deepika Gujjarlapudi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Deepika Gujjarlapudi has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Duvvuru Nageshwar Reddy
Department of Gastroenterology, AIG Hospitals, Hyderabad, India
5 shared publications Nageshwar Reddy Duvvur
4 shared publicationsNamburu Veeraiah
4 shared publicationsAnkit Mittal
Department of Infectious Diseases, Asian Institute of Gastroenterology, Gachibowli, Hyderabad, Telangana, India
3 shared publicationsVidyavathi Devi Gajapathi Raju
3 shared publications- Anand V. Kulkarni
Department of Hepatology, AIG Hospitals, Hyderabad, India
2 shared publications
Latest Publications
- 1 December 2026
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 20 (12) , BC01-BC07
Analytical Validation of Routine Chemistry Analytes in Miscellaneous Body Fluids Using the Beckman Coulter AU5800 Analyser: An Experimental Study
Introduction: Fluids are not routinely validated by the company’s manufacturers as a routine process, highlighting the need for laboratory physicians to establish a protocol and research the performance characteristics of analytes in bodily fluids in order to provide more accurate and precise results for improving the standard of patient care. Aim: To validate the adaptation of serum kits of the Beckman Coulter system for use in pleural, ascitic and Jackson-Pratt (JP) drain fluids for common routine chemistry analytes. Materials and Methods: This experimental study was conducted in the Department of Biochemistry, Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad, Telangana, India. The samples were collected in December 2024 for a period of seven days from December 3rd 2024, to December 10th 2024. A sample size of about 20 fluid samples was collected over the course of seven days (one week), as per Clinical and Laboratory Standards Institute (CLSI) guidelines. Accuracy, precision, linearity and carry-over studies were carried out for nine parameters in ascitic, pleural and JP drain fluids. Results: Accuracy studies showed recovery rates of 98.2- 100.2%, against Beckman Coulter serum certified reference material, consistent with expected values, and interlaboratory comparisons indicated acceptable bias. Linearity demonstrated strong correlation (r=0.98-1.0) in 20 samples for each fluid that is in ascitic, pleural, and JP drain fluids, across all analytes, confirming reliability at higher concentrations. Precision analysis (intra-day and inter-assay) revealed CV% consistently below 5%, with pleural and ascitic fluids showing excellent reproducibility. Carry-over for all nine analytes in 20 samples for each fluid (pleural, ascitic and JP drain) showed acceptable error limit that is not more than three standard deviation as well as carry-over that is within 1% of the high sample concentration. Total protein (0.02) and albumin (0.00) in pleural fluid and Amylase (0.06) in ascitic fluid showed excellent carry-over across all parameters. Conclusion: Validation of serum chemistry assays for body fluids is essential to ensure reliable laboratory reporting, as these specimens are not routinely validated by manufacturers. The present study demonstrated satisfactory analytical performance for common chemistry analytes in pleural, ascitic, and JP drain fluids using the Beckman Coulter system. Implementing standardised in-house validation protocols can improve result accuracy, enhance confidence in clinical interpretation, and contribute to better patient care.
- 1 December 2026
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 20 (12) , BC01-BC07
Analytical Validation of Routine Chemistry Analytes in Miscellaneous Body Fluids Using the Beckman Coulter AU5800 Analyser: An Experimental Study
Introduction: Fluids are not routinely validated by the company’s manufacturers as a routine process, highlighting the need for laboratory physicians to establish a protocol and research the performance characteristics of analytes in bodily fluids in order to provide more accurate and precise results for improving the standard of patient care. Aim: To validate the adaptation of serum kits of the Beckman Coulter system for use in pleural, ascitic and Jackson-Pratt (JP) drain fluids for common routine chemistry analytes. Materials and Methods: This experimental study was conducted in the Department of Biochemistry, Asian Institute of Gastroenterology (AIG) Hospitals, Hyderabad, Telangana, India. The samples were collected in December 2024 for a period of seven days from December 3rd 2024, to December 10th 2024. A sample size of about 20 fluid samples was collected over the course of seven days (one week), as per Clinical and Laboratory Standards Institute (CLSI) guidelines. Accuracy, precision, linearity and carry-over studies were carried out for nine parameters in ascitic, pleural and JP drain fluids. Results: Accuracy studies showed recovery rates of 98.2- 100.2%, against Beckman Coulter serum certified reference material, consistent with expected values, and interlaboratory comparisons indicated acceptable bias. Linearity demonstrated strong correlation (r=0.98-1.0) in 20 samples for each fluid that is in ascitic, pleural, and JP drain fluids, across all analytes, confirming reliability at higher concentrations. Precision analysis (intra-day and inter-assay) revealed CV% consistently below 5%, with pleural and ascitic fluids showing excellent reproducibility. Carry-over for all nine analytes in 20 samples for each fluid (pleural, ascitic and JP drain) showed acceptable error limit that is not more than three standard deviation as well as carry-over that is within 1% of the high sample concentration. Total protein (0.02) and albumin (0.00) in pleural fluid and Amylase (0.06) in ascitic fluid showed excellent carry-over across all parameters. Conclusion: Validation of serum chemistry assays for body fluids is essential to ensure reliable laboratory reporting, as these specimens are not routinely validated by manufacturers. The present study demonstrated satisfactory analytical performance for common chemistry analytes in pleural, ascitic, and JP drain fluids using the Beckman Coulter system. Implementing standardised in-house validation protocols can improve result accuracy, enhance confidence in clinical interpretation, and contribute to better patient care.
- Open Access
Comparative Diagnostic Performance of AFP, PIVKA-II, and the ASAP Score for Hepatocellular Carcinoma: A Large Tertiary Care Referral Center Study from India
Background: Alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-Il) are established biomarkers for hepatocellular carcinoma (HCC). The ASAP score, incorporating age, sex, AFP, and PIVKA-II, may improve diagnosis, but data from Indian populations are limited. We compared the diagnostic performance of AFP, PIVKA-II, and ASAP in a large tertiary referral cohort from India. Methods: In this single-center cross-sectional study, consecutive adults with chronic liver disease and healthy controls evaluated at AIG Hospitals, Hyderabad, from January to December 2025 were included. HCC was diagnosed using standard imaging criteria. AFP and PIVKA-II were measured by a chemiluminescent microparticle immunoassay, and ASAP was calculated for each participant. Diagnostic performance was assessed using receiver operating characteristic (ROC) and precision–recall analyses at standard and optimized cut-offs derived from the Youden index and F1-score. Results: Among 1305 participants, 686 were cirrhotic controls, 278 had cirrhotic HCC, 130 were non-cirrhotic controls, and 37 had non-cirrhotic HCC. At standard cut-offs, AFP (20 ng/mL) showed high specificity but low sensitivity, especially for early-stage HCC (93.3% and 29.6%). PIVKA-II (40 mAU/mL) showed high sensitivity but poor specificity (82.7% and 26.4%). ASAP (0.526) provided the best balance, with 69.4% sensitivity and 52.2% specificity in early-stage HCC, 82.0% and 52.2% in cirrhotic HCC, and 81.9% and 55.5% overall. ROC analysis demonstrated superior discrimination for ASAP across cirrhotic, non-cirrhotic, and etiologic subgroups, including metabolic-dysfunction-associated steatotic liver disease (MASLD) HCC. Optimized cut-offs, particularly higher thresholds for PIVKA-II (71.3–98.1 mAU/mL) and ASAP (0.6–0.9), improved the diagnostic balance. Conclusions: The ASAP score modestly outperforms AFP and PIVKA-II, offering better overall diagnostic accuracy for HCC in a MASLD-dominant cohort. Lower cut-offs may improve early detection, but performance in very-early-stage disease remains suboptimal and hence there is limited benefit in surveillance-relevant settings. Higher population-specific cut-offs are required for Indian populations. These findings support the use of these biomarkers as complementary tools alongside imaging for risk stratification rather than standalone screening tests.
Open AccessComparative Diagnostic Performance of AFP, PIVKA-II, and the ASAP Score for Hepatocellular Carcinoma: A Large Tertiary Care Referral Center Study from India
Background: Alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-Il) are established biomarkers for hepatocellular carcinoma (HCC). The ASAP score, incorporating age, sex, AFP, and PIVKA-II, may improve diagnosis, but data from Indian populations are limited. We compared the diagnostic performance of AFP, PIVKA-II, and ASAP in a large tertiary referral cohort from India. Methods: In this single-center cross-sectional study, consecutive adults with chronic liver disease and healthy controls evaluated at AIG Hospitals, Hyderabad, from January to December 2025 were included. HCC was diagnosed using standard imaging criteria. AFP and PIVKA-II were measured by a chemiluminescent microparticle immunoassay, and ASAP was calculated for each participant. Diagnostic performance was assessed using receiver operating characteristic (ROC) and precision–recall analyses at standard and optimized cut-offs derived from the Youden index and F1-score. Results: Among 1305 participants, 686 were cirrhotic controls, 278 had cirrhotic HCC, 130 were non-cirrhotic controls, and 37 had non-cirrhotic HCC. At standard cut-offs, AFP (20 ng/mL) showed high specificity but low sensitivity, especially for early-stage HCC (93.3% and 29.6%). PIVKA-II (40 mAU/mL) showed high sensitivity but poor specificity (82.7% and 26.4%). ASAP (0.526) provided the best balance, with 69.4% sensitivity and 52.2% specificity in early-stage HCC, 82.0% and 52.2% in cirrhotic HCC, and 81.9% and 55.5% overall. ROC analysis demonstrated superior discrimination for ASAP across cirrhotic, non-cirrhotic, and etiologic subgroups, including metabolic-dysfunction-associated steatotic liver disease (MASLD) HCC. Optimized cut-offs, particularly higher thresholds for PIVKA-II (71.3–98.1 mAU/mL) and ASAP (0.6–0.9), improved the diagnostic balance. Conclusions: The ASAP score modestly outperforms AFP and PIVKA-II, offering better overall diagnostic accuracy for HCC in a MASLD-dominant cohort. Lower cut-offs may improve early detection, but performance in very-early-stage disease remains suboptimal and hence there is limited benefit in surveillance-relevant settings. Higher population-specific cut-offs are required for Indian populations. These findings support the use of these biomarkers as complementary tools alongside imaging for risk stratification rather than standalone screening tests.
- Open Access
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
Dual-Task Explainable TabNet for Joint Chronic Kidney and Cardiovascular Disease Risk Prediction in Non-Alcoholic Fatty Liver Disease
Background: Chronic kidney disease (CKD) and cardiovascular disease (CVD) frequently co-occur in non-alcoholic fatty liver disease (NAFLD), but CKD staging is defined directly from renal biomarkers, risking models that merely recover it.Methods: In 1,500 NAFLD patients, we benchmarked Dual-Task Explainable TabNet (DT-XTabNet) — a partial-sharing architecture with a novel Attention Divergence Regularization (ADR) loss — against six classical and three deep-learning baselines. Three pre-specified feature sets were compared: the full 54-variable panel; a broad 50-variable non-renal panel; and a curated 14-variable metabolic/hepatic panel. Bootstrap CIs, DeLong’s test, decision curve analysis, and reclassification metrics (NRI, IDI) quantified value beyond age and sex.Findings: DT-XTabNet achieved full-panel CKD AUC 0.985, CVD AUC 0.882, non-inferior to two independent TabNets at 42.8% of the parameters. eGFR alone achieved AUC 0.990 for CKD, confirming circularity. On the curated panel, CKD AUC fell to 0.631 (95% CI 0.604–0.660) but added no value over age and sex alone (0.636; NRI≈0, IDI=0.002). CVD discrimination was preserved (AUC 0.869, 95% CI 0.851–0.886) with clear incremental value over age and sex (0.645; NRI=0.34, IDI=0.39). Gradient boosting remained superior for CVD (ΔAUC=−0.073, p<0.0001).Interpretation: Because CKD stage is algebraically defined from its own predictors, this task is risk stratification within a diagnostically defined cohort, not independent prediction. The curated panel yields a substantial, renal-independent CVD signal but a marginal, age/sex-attributable CKD signal. DT-XTabNet offers parameter-efficient, non-inferior multi-outcome prediction with an interpretable regularization mechanism, but does not exceed gradient boosting for CVD; its case rests on deployment governance, not speed.
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDual-Task Explainable TabNet for Joint Chronic Kidney and Cardiovascular Disease Risk Prediction in Non-Alcoholic Fatty Liver Disease
Background: Chronic kidney disease (CKD) and cardiovascular disease (CVD) frequently co-occur in non-alcoholic fatty liver disease (NAFLD), but CKD staging is defined directly from renal biomarkers, risking models that merely recover it.Methods: In 1,500 NAFLD patients, we benchmarked Dual-Task Explainable TabNet (DT-XTabNet) — a partial-sharing architecture with a novel Attention Divergence Regularization (ADR) loss — against six classical and three deep-learning baselines. Three pre-specified feature sets were compared: the full 54-variable panel; a broad 50-variable non-renal panel; and a curated 14-variable metabolic/hepatic panel. Bootstrap CIs, DeLong’s test, decision curve analysis, and reclassification metrics (NRI, IDI) quantified value beyond age and sex.Findings: DT-XTabNet achieved full-panel CKD AUC 0.985, CVD AUC 0.882, non-inferior to two independent TabNets at 42.8% of the parameters. eGFR alone achieved AUC 0.990 for CKD, confirming circularity. On the curated panel, CKD AUC fell to 0.631 (95% CI 0.604–0.660) but added no value over age and sex alone (0.636; NRI≈0, IDI=0.002). CVD discrimination was preserved (AUC 0.869, 95% CI 0.851–0.886) with clear incremental value over age and sex (0.645; NRI=0.34, IDI=0.39). Gradient boosting remained superior for CVD (ΔAUC=−0.073, p<0.0001).Interpretation: Because CKD stage is algebraically defined from its own predictors, this task is risk stratification within a diagnostically defined cohort, not independent prediction. The curated panel yields a substantial, renal-independent CVD signal but a marginal, age/sex-attributable CKD signal. DT-XTabNet offers parameter-efficient, non-inferior multi-outcome prediction with an interpretable regularization mechanism, but does not exceed gradient boosting for CVD; its case rests on deployment governance, not speed.
- Open Access
- 21 July 2025
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 14 (7) , 2885-2891
COVID-19 vaccination-infection status and immunological profile from India: A case study for prioritizing at risk population for targeted immunization
Background: The COVID-19 pandemic’s global impact was mitigated through rapid vaccine development, leading to a mix of natural and vaccination-derived immunity. The immunological profile in hybrid immunity remains less studied, especially in regions where non-mRNA vaccines were used. This study focuses on the immunological profiles and predictors of immune response in one such population. Methods: This cohort study assessed their humoral and cellular immune responses, breakthrough Omicron infections, and hospitalization rates based on vaccination and infection history. Immunological assays to measure anti-spike protein and neutralizing antibodies and interferon-γ release assay were performed. Regression models were used to estimate predictors of immune response and hospitalization in patients with breakthrough infections. Results: The study revealed significant differences in immune response among participants based on their hybrid immunity status, vaccination, and infection history. Higher antibody titers and cellular responses were observed in individuals with hybrid immunity, especially those with dual pre-Omicron and Omicron infections (3326 BAU/ml, IQR: 770.25–5678.25 and 4.92 IU of IFN-γ/mL, respectively, P < 0.001). Age, hypertension, baseline antibody levels, and vaccination status were found to predict humoral response. Baseline antibody levels were found to be predictive of hospitalization, and no participants with an antibody titer >250 BAU/mL required hospitalization. Conclusion: Hybrid immunity is linked to a stronger humoral and cellular immune response, and elevated antibody titers can serve as a surrogate marker for protection against hospitalization. These findings highlight the need to prioritize high-risk groups, such as older adults and individuals with comorbidities, for booster vaccinations to strengthen community-level defenses against COVID-19.
- 21 July 2025
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 14 (7) , 2885-2891
Open AccessCOVID-19 vaccination-infection status and immunological profile from India: A case study for prioritizing at risk population for targeted immunization
Background: The COVID-19 pandemic’s global impact was mitigated through rapid vaccine development, leading to a mix of natural and vaccination-derived immunity. The immunological profile in hybrid immunity remains less studied, especially in regions where non-mRNA vaccines were used. This study focuses on the immunological profiles and predictors of immune response in one such population. Methods: This cohort study assessed their humoral and cellular immune responses, breakthrough Omicron infections, and hospitalization rates based on vaccination and infection history. Immunological assays to measure anti-spike protein and neutralizing antibodies and interferon-γ release assay were performed. Regression models were used to estimate predictors of immune response and hospitalization in patients with breakthrough infections. Results: The study revealed significant differences in immune response among participants based on their hybrid immunity status, vaccination, and infection history. Higher antibody titers and cellular responses were observed in individuals with hybrid immunity, especially those with dual pre-Omicron and Omicron infections (3326 BAU/ml, IQR: 770.25–5678.25 and 4.92 IU of IFN-γ/mL, respectively, P < 0.001). Age, hypertension, baseline antibody levels, and vaccination status were found to predict humoral response. Baseline antibody levels were found to be predictive of hospitalization, and no participants with an antibody titer >250 BAU/mL required hospitalization. Conclusion: Hybrid immunity is linked to a stronger humoral and cellular immune response, and elevated antibody titers can serve as a surrogate marker for protection against hospitalization. These findings highlight the need to prioritize high-risk groups, such as older adults and individuals with comorbidities, for booster vaccinations to strengthen community-level defenses against COVID-19.
- Open Access
Human Metapneumovirus seroprevalence and PCR trends - Findings from a Tertiary Care Hospital in India
Human Metapneumovirus (hMPV) is a paramyxovirus that was detected in India first in 2004. It causes a mild common cold in most cases but serious illness has been reported in some young children, adults >65 years and the immunocompromised. AIM: To study the age related prevalence of IgG antibodies in the population and also to determine the percent positivity and seasonal variation of hMPV infection. MATERIAL AND METHODS: This cross-sectional study assessed seroprevalence by testing 820 serum samples collected between January 25 th – 31 st 2025 for hMPV IgG antibodies by ELISA and stratified according to age and sex. hMPV PCR trends: Retrospective data from the 1276 tests for Respiratory Viruses done at our centre during 2023 and 2024 were analysed and comprised of age groups 0-18, 19-30 ,31-45, 45-60 and > 60 years. The relationship between gender (M/F) and outcome (positive/negative) across various age groups was analysed using the chi-square test for independence in Graph Pad Prism 8.0. RESULTS: Seroprevalence study: Overall hMPV IgG Antibody Positivity was 53.4%. Antibody positivity was higher in above 60 years when compared to other groups and was statistically significant (P=0.0001) and female predominance is seen. In hMPV PCR trends: A higher percentage of positivity were observed in > 60years individuals who had hospitalisation when compared to the other groups which was statistically significant(P=0.0001). Overall Percent positivity was 7.8% in 2023 and 3.8% in 2024. Seasonal peaks occurred in Feb-Mar and Oct. 92.6% of patients were discharged and doing well on follow-up and only 7.4% deaths were seen. CONCLUSION: Our findings highlight around 53.4% of the total study population had hMPV IgG antibodies. PCR positivity and antibody positivity was higher in individuals over 60 who had other comorbidities. Hospitalization and mortality rates are significantly high in this high risk groups. Vaccine development for high-risk individuals is recommended.
Open AccessHuman Metapneumovirus seroprevalence and PCR trends - Findings from a Tertiary Care Hospital in India
Human Metapneumovirus (hMPV) is a paramyxovirus that was detected in India first in 2004. It causes a mild common cold in most cases but serious illness has been reported in some young children, adults >65 years and the immunocompromised. AIM: To study the age related prevalence of IgG antibodies in the population and also to determine the percent positivity and seasonal variation of hMPV infection. MATERIAL AND METHODS: This cross-sectional study assessed seroprevalence by testing 820 serum samples collected between January 25 th – 31 st 2025 for hMPV IgG antibodies by ELISA and stratified according to age and sex. hMPV PCR trends: Retrospective data from the 1276 tests for Respiratory Viruses done at our centre during 2023 and 2024 were analysed and comprised of age groups 0-18, 19-30 ,31-45, 45-60 and > 60 years. The relationship between gender (M/F) and outcome (positive/negative) across various age groups was analysed using the chi-square test for independence in Graph Pad Prism 8.0. RESULTS: Seroprevalence study: Overall hMPV IgG Antibody Positivity was 53.4%. Antibody positivity was higher in above 60 years when compared to other groups and was statistically significant (P=0.0001) and female predominance is seen. In hMPV PCR trends: A higher percentage of positivity were observed in > 60years individuals who had hospitalisation when compared to the other groups which was statistically significant(P=0.0001). Overall Percent positivity was 7.8% in 2023 and 3.8% in 2024. Seasonal peaks occurred in Feb-Mar and Oct. 92.6% of patients were discharged and doing well on follow-up and only 7.4% deaths were seen. CONCLUSION: Our findings highlight around 53.4% of the total study population had hMPV IgG antibodies. PCR positivity and antibody positivity was higher in individuals over 60 who had other comorbidities. Hospitalization and mortality rates are significantly high in this high risk groups. Vaccine development for high-risk individuals is recommended.
- Open Access
COVID-19 vaccination-infection status and immunological profile from India: a case study for prioritizing at risk population for targeted immunization
Background: The COVID-19 pandemic’s global impact was mitigated through rapid vaccine development, leading to a mix of natural and vaccination-derived immunity. Immunological profile in hybrid immunity remains less studies, especially in regions where non-mRNA vaccines were used. This study focuses on the immunological profiles and predictors of immune response in one such population. Methods: This was a cross-sectional study to assess their humoral and cellular immune responses based on vaccination and infection history. Immunological assays were performed to measure antispike protein and neutralizing antibodies as well as interferon-γ release assay. Multivariable linear regression model was used to estimate predictors of immune response. Results: The study revealed significant differences in immune response among participants based on their hybrid immunity status, vaccination, and infection history. Higher antibody titres and cellular responses were observed in individuals with hybrid immunity, especially those with dual pre-Omicron and Omicron infections (3326 BAU/ml, IQR: 770.25-5678.25 and 4.92 IU of IFN-γ/mL, IQR:3.74-16.98 respectively, p <0.001). Age and comorbidities such as diabetes and hypertension were associated with lower antibody levels and cellular response, while vaccination and hybrid immunity correlated with higher immune responses. Conclusion: The prevalence of hybrid immunity was high, yet a substantial portion of the population lacks it, indicating the necessity for targeted immunization strategies. The findings underscore the importance of prioritizing high-risk individuals, such as elderly and individuals with comorbidities, for booster vaccinations to enhance community-level protection against COVID-19.
Open AccessCOVID-19 vaccination-infection status and immunological profile from India: a case study for prioritizing at risk population for targeted immunization
Background: The COVID-19 pandemic’s global impact was mitigated through rapid vaccine development, leading to a mix of natural and vaccination-derived immunity. Immunological profile in hybrid immunity remains less studies, especially in regions where non-mRNA vaccines were used. This study focuses on the immunological profiles and predictors of immune response in one such population. Methods: This was a cross-sectional study to assess their humoral and cellular immune responses based on vaccination and infection history. Immunological assays were performed to measure antispike protein and neutralizing antibodies as well as interferon-γ release assay. Multivariable linear regression model was used to estimate predictors of immune response. Results: The study revealed significant differences in immune response among participants based on their hybrid immunity status, vaccination, and infection history. Higher antibody titres and cellular responses were observed in individuals with hybrid immunity, especially those with dual pre-Omicron and Omicron infections (3326 BAU/ml, IQR: 770.25-5678.25 and 4.92 IU of IFN-γ/mL, IQR:3.74-16.98 respectively, p <0.001). Age and comorbidities such as diabetes and hypertension were associated with lower antibody levels and cellular response, while vaccination and hybrid immunity correlated with higher immune responses. Conclusion: The prevalence of hybrid immunity was high, yet a substantial portion of the population lacks it, indicating the necessity for targeted immunization strategies. The findings underscore the importance of prioritizing high-risk individuals, such as elderly and individuals with comorbidities, for booster vaccinations to enhance community-level protection against COVID-19.
- 9 November 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (5) , 864-874
Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial
INTRODUCTION: Critically ill patients with cirrhosis admitted to the intensive care unit (ICU) are usually on broad-spectrum antibiotics because of suspected infection or as a hospital protocol. It is unclear if additional rifaximin has any synergistic effect with broad-spectrum antibiotics in ICU patients with acute overt hepatic encephalopathy (HE). METHODS: In this double-blind trial, patients with overt HE admitted to ICU were randomized to receive antibiotics (ab) alone or antibiotics with rifaximin (ab + r). Resolution (or 2 grade reduction) of HE, time to resolution of HE, in-hospital mortality, nosocomial infection, and changes in endotoxin levels were compared between the 2 groups. A subgroup analysis of patients with decompensated cirrhosis and acute-on-chronic liver failure was performed. RESULTS: Baseline characteristics and severity scores were similar among both groups (92 in each group). Carbapenems and cephalosporin with beta-lactamase inhibitors were the most commonly used ab. On Kaplan-Meier analysis, 44.6% (41/92; 95% confidence interval [CI], 32–70.5) in ab-only arm and 46.7% (43/92; 95% CI, 33.8–63) in ab + r arm achieved the primary objective (P = 0.84).Time to achieve the primary objective (3.65 ± 1.82 days and 4.11 ± 2.01 days; P = 0.27) and in-hospital mortality were similar among both groups (62% vs 50%; P = 0.13). Seven percent and 13% in the ab and ab + r groups developed nosocomial infections (P = 0.21). Endotoxin levels were unaffected by rifaximin. Rifaximin led to lower in-hospital mortality (hazard ratio: 0.39 [95% CI, 0.2–0.76]) in patients with decompensated cirrhosis but not in patients with acute-on-chronic liver failure (hazard ratio: 0.99 [95% CI, 0.6–1.63]) because of reduced nosocomial infections. DISCUSSION: Reversal of overt HE in those on ab was comparable with those on ab + r.
- 9 November 2023
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (5) , 864-874
Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial
INTRODUCTION: Critically ill patients with cirrhosis admitted to the intensive care unit (ICU) are usually on broad-spectrum antibiotics because of suspected infection or as a hospital protocol. It is unclear if additional rifaximin has any synergistic effect with broad-spectrum antibiotics in ICU patients with acute overt hepatic encephalopathy (HE). METHODS: In this double-blind trial, patients with overt HE admitted to ICU were randomized to receive antibiotics (ab) alone or antibiotics with rifaximin (ab + r). Resolution (or 2 grade reduction) of HE, time to resolution of HE, in-hospital mortality, nosocomial infection, and changes in endotoxin levels were compared between the 2 groups. A subgroup analysis of patients with decompensated cirrhosis and acute-on-chronic liver failure was performed. RESULTS: Baseline characteristics and severity scores were similar among both groups (92 in each group). Carbapenems and cephalosporin with beta-lactamase inhibitors were the most commonly used ab. On Kaplan-Meier analysis, 44.6% (41/92; 95% confidence interval [CI], 32–70.5) in ab-only arm and 46.7% (43/92; 95% CI, 33.8–63) in ab + r arm achieved the primary objective (P = 0.84).Time to achieve the primary objective (3.65 ± 1.82 days and 4.11 ± 2.01 days; P = 0.27) and in-hospital mortality were similar among both groups (62% vs 50%; P = 0.13). Seven percent and 13% in the ab and ab + r groups developed nosocomial infections (P = 0.21). Endotoxin levels were unaffected by rifaximin. Rifaximin led to lower in-hospital mortality (hazard ratio: 0.39 [95% CI, 0.2–0.76]) in patients with decompensated cirrhosis but not in patients with acute-on-chronic liver failure (hazard ratio: 0.99 [95% CI, 0.6–1.63]) because of reduced nosocomial infections. DISCUSSION: Reversal of overt HE in those on ab was comparable with those on ab + r.
- Open Access
- 23 August 2023
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 15 (3) , 556-562
Adverse Events Following Immunization of COVID-19 Vaccines: A Tertiary Care Hospital-Based Study from South Indian Population
G Deepika1, S Gokul1, Meghana Vadlamudi1, K Punnagai2, N Raja3 and Sabitha Panchagiri1* Author informationArticle notesCopyright and License informationPDFCitations Corresponding author. Correspondence: Dr. Sabitha Panchagiri Associate Professor, Department of Pharmacy Practice, Sri Ramachnadra Faculty of Pharmacy SRIHER, Porur, Chennai, Tamil Nadu – 600116. INDIA. Email: sabithap@sriramachandra.edu.in Received February 24, 2023; Revised March 29, 2023; Accepted
- 23 August 2023
- Published by Manuscript Technomedia LLP in Journal of Young Pharmacists
- Vol. 15 (3) , 556-562
Open AccessAdverse Events Following Immunization of COVID-19 Vaccines: A Tertiary Care Hospital-Based Study from South Indian Population
G Deepika1, S Gokul1, Meghana Vadlamudi1, K Punnagai2, N Raja3 and Sabitha Panchagiri1* Author informationArticle notesCopyright and License informationPDFCitations Corresponding author. Correspondence: Dr. Sabitha Panchagiri Associate Professor, Department of Pharmacy Practice, Sri Ramachnadra Faculty of Pharmacy SRIHER, Porur, Chennai, Tamil Nadu – 600116. INDIA. Email: sabithap@sriramachandra.edu.in Received February 24, 2023; Revised March 29, 2023; Accepted
- Open Access
- 6 February 2023
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (03) , 377-382
Effect of COVID-19 Vaccination on the Levels of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Naive, Hybrid, and Breakthrough SARS-CoV-2 Recovered Indian Individuals
Introduction Vaccination has shown to be protective against severe coronavirus disease 2019 by various studies. However, the vaccine efficacy was demonstrated to be less against the emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both vaccine- and infection-induced immunity against SARS-CoV-2 may prevent reinfection and severity. Our study aims to assess and compare the humoral response in heterogeneous population based on infection and vaccination status along with hybrid immunity. Methods A retrospective, observational study of 2,545 adults was conducted. The study groups comprised of group I (n = 309) naive with a single dose of vaccination, group II (n = 357) infected and unvaccinated, group III (n = 590) completely vaccinated with two doses of vaccine, group IV (n = 70) booster dose, group V (n = 602) with hybrid immunity (pre-vaccination infection), and group VI (n = 617) with breakthrough infection (post-vaccination infection). Data pertaining to demographic details, clinical presentations, reverse transcription-polymerase chain reaction, anti-SARS-CoV-2 total antibodies immunoglobulin G (IgG), neutralizing antibodies by anti SARS-CoV-2 sVNT (surrogate virus neutralization test), S1/S2IgG, S-RBD (receptor-binding domain), and ChAdOx1-nCov-19 (Covishield) vaccination were retrieved from electronic health records. Results The mean levels of neutralizing antibodies of group V were S1/S2, RBD (10.5/14.3 times), and sVNT (84.44%) and group VI had S1/S2, RBD (11.4/11.8 times), and sVNT (78.07%) when compared to group III. We also observed a statistically significant higher immune response in group V and VI than group I and II. A higher percentage (18.2%) of group II individuals had severe disease when compared to group V and VI (6.5/10.8%). Conclusion A single dose of ChAdOx1 vaccine gives robust antibody responses in previously infected individuals and may confer long-term hybrid immunity following booster vaccination.
- 6 February 2023
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (03) , 377-382
Open AccessEffect of COVID-19 Vaccination on the Levels of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Naive, Hybrid, and Breakthrough SARS-CoV-2 Recovered Indian Individuals
Introduction Vaccination has shown to be protective against severe coronavirus disease 2019 by various studies. However, the vaccine efficacy was demonstrated to be less against the emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Both vaccine- and infection-induced immunity against SARS-CoV-2 may prevent reinfection and severity. Our study aims to assess and compare the humoral response in heterogeneous population based on infection and vaccination status along with hybrid immunity. Methods A retrospective, observational study of 2,545 adults was conducted. The study groups comprised of group I (n = 309) naive with a single dose of vaccination, group II (n = 357) infected and unvaccinated, group III (n = 590) completely vaccinated with two doses of vaccine, group IV (n = 70) booster dose, group V (n = 602) with hybrid immunity (pre-vaccination infection), and group VI (n = 617) with breakthrough infection (post-vaccination infection). Data pertaining to demographic details, clinical presentations, reverse transcription-polymerase chain reaction, anti-SARS-CoV-2 total antibodies immunoglobulin G (IgG), neutralizing antibodies by anti SARS-CoV-2 sVNT (surrogate virus neutralization test), S1/S2IgG, S-RBD (receptor-binding domain), and ChAdOx1-nCov-19 (Covishield) vaccination were retrieved from electronic health records. Results The mean levels of neutralizing antibodies of group V were S1/S2, RBD (10.5/14.3 times), and sVNT (84.44%) and group VI had S1/S2, RBD (11.4/11.8 times), and sVNT (78.07%) when compared to group III. We also observed a statistically significant higher immune response in group V and VI than group I and II. A higher percentage (18.2%) of group II individuals had severe disease when compared to group V and VI (6.5/10.8%). Conclusion A single dose of ChAdOx1 vaccine gives robust antibody responses in previously infected individuals and may confer long-term hybrid immunity following booster vaccination.
- Open Access
- 31 January 2023
- Published by Wiley in Critical Care Research and Practice
- Vol. 2023 (1) , 4174241
Association of Lower Antispike Antibody Levels with Mortality in ICU Patients with COVID‐19 Disease
Background. Though vaccines have been reported as highly efficacious in preventing severe COVID‐19 disease, there is emerging data of severe infections, albeit a small number, in vaccinated individuals. We have conducted a retrospective observational study to assess the clinical characteristics, immunological response, and disease outcomes among the vaccinated and unvaccinated patients admitted to the ICU with severe COVID‐19 disease. Methods. Study Design and Participants. We conducted a retrospective observational study in COVID ICU of a tertiary care hospital. Data were collected from the month of 1 April 2021 to 31 November 2021. All adult patients admitted to the ICU having severe COVID‐19 disease were included in the study. Data were collected from the medical records database which included demographics, a clinical course in the ICU, laboratory and radiological parameters, and disease outcomes. In a subset of patients, cell‐mediated immunity and S1S2‐neutralising antibody assessment was done. Results. A total of 419 patients with severe COVID‐19 were included in the study. Of the 419 patients, 90 (21.5%) were vaccinated, and 329 (78.5%) were unvaccinated. There was a significantly higher mortality in unvaccinated severe COVID 19 patients as compared to vaccinated severe COVID patients (46.2% vs 34.4%; P < 0.0455). The neutralizing antibody titre was significantly higher in survivors as compared to nonsurvivors (2139.8, SE ± 713.3 vs 471, SE ± 154.4); P < 0.026. Conclusion. Our study suggests the association of lower neutralizing antibody levels with mortality in ICU patients admitted with COVID‐19 breakthrough infections.
- 31 January 2023
- Published by Wiley in Critical Care Research and Practice
- Vol. 2023 (1) , 4174241
Open AccessAssociation of Lower Antispike Antibody Levels with Mortality in ICU Patients with COVID‐19 Disease
Background. Though vaccines have been reported as highly efficacious in preventing severe COVID‐19 disease, there is emerging data of severe infections, albeit a small number, in vaccinated individuals. We have conducted a retrospective observational study to assess the clinical characteristics, immunological response, and disease outcomes among the vaccinated and unvaccinated patients admitted to the ICU with severe COVID‐19 disease. Methods. Study Design and Participants. We conducted a retrospective observational study in COVID ICU of a tertiary care hospital. Data were collected from the month of 1 April 2021 to 31 November 2021. All adult patients admitted to the ICU having severe COVID‐19 disease were included in the study. Data were collected from the medical records database which included demographics, a clinical course in the ICU, laboratory and radiological parameters, and disease outcomes. In a subset of patients, cell‐mediated immunity and S1S2‐neutralising antibody assessment was done. Results. A total of 419 patients with severe COVID‐19 were included in the study. Of the 419 patients, 90 (21.5%) were vaccinated, and 329 (78.5%) were unvaccinated. There was a significantly higher mortality in unvaccinated severe COVID 19 patients as compared to vaccinated severe COVID patients (46.2% vs 34.4%; P < 0.0455). The neutralizing antibody titre was significantly higher in survivors as compared to nonsurvivors (2139.8, SE ± 713.3 vs 471, SE ± 154.4); P < 0.026. Conclusion. Our study suggests the association of lower neutralizing antibody levels with mortality in ICU patients admitted with COVID‐19 breakthrough infections.